Lin Hung-Lung, Lin Ming-Yen, Tsai Cheng-Hsun, Wang Yi-Hsiu, Chen Chung-Jen, Hwang Shang-Jyh, Yen Ming-Hong, Chiu Yi-Wen
Department of Chinese Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Front Pharmacol. 2021 Apr 29;12:573145. doi: 10.3389/fphar.2021.573145. eCollection 2021.
Harmonizing formulas are associated with beneficial renal outcomes in chronic kidney disease (CKD), but the therapeutic mechanisms are unclear. The study aims to explore the associations of intentions and independent factors with harmonizing formulas prescriptions for patients with CKD. We conducted a population-based cross-sectional study to explore factors associated with harmonizing formulas prescription. Patients who had been prescribed harmonizing formulas after CKD diagnosis was defined as the using harmonizing formulas group. Disease diagnoses when having harmonizing formula prescriptions and patient characteristics related to these prescriptions were collected. In total, 24,971 patients were enrolled in this analysis, and 5,237 (21%) patients were prescribed harmonizing formulas after CKD diagnosis. The three most frequent systematic diseases and related health problems for which harmonizing formula prescriptions were issued in CKD were symptoms, signs, and ill-defined conditions (24.5%), diseases of the digestive system (20.67%), and diseases of the musculoskeletal system (12.9%). Higher likelihoods of harmonizing formula prescriptions were associated with young age (adjusted odds ratio: 0.98, 95% confidence interval: 0.97-0.98), female sex (1.79, 1.68-1.91), no diabetes (1.20, 1.06-1.36), no hypertension (1.38, 1.27-1.50), no cerebrovascular disease (1.34, 1.14-1.56), less disease severity (0.85, 0.83-0.88), using nonsteroidal anti-inflammatory drugs (NSAIDs) (1.65, 1.54-1.78), and using analgesic drugs other than NSAIDs (1.47, 1.35-1.59). Harmonizing formulas are commonly used for treating symptoms of the digestive and musculoskeletal systems in CKD cases. Further research on harmonizing formula effectiveness with regard to particular characteristics of CKD patients is warranted.
和剂方与慢性肾脏病（CKD）患者有益的肾脏结局相关，但治疗机制尚不清楚。本研究旨在探讨CKD患者使用和剂方的意图及独立因素。我们开展了一项基于人群的横断面研究，以探究与和剂方处方相关的因素。CKD诊断后接受和剂方处方的患者被定义为使用和剂方组。收集了开具和剂方时的疾病诊断以及与这些处方相关的患者特征。本分析共纳入24,971例患者，其中5,237例（21%）患者在CKD诊断后接受了和剂方处方。CKD患者开具和剂方最常见的三种系统性疾病及相关健康问题为症状、体征和未明确的病症（24.5%）、消化系统疾病（20.67%）以及肌肉骨骼系统疾病（12.9%）。和剂方处方可能性较高与以下因素相关：年轻（调整优势比：0.98，95%置信区间：0.97 - 0.98）、女性（1.79，1.68 - 1.91）、无糖尿病（1.20，1.06 - 1.36）、无高血压（1.38，1.27 - 1.50）、无脑血管疾病（1.34，1.14 - 1.56）、疾病严重程度较低（0.85，0.83 - 0.88）、使用非甾体抗炎药（NSAIDs）（1.65，1.54 - 1.78）以及使用非NSAIDs类镇痛药（1.47，1.35 - 1.59）。和剂方常用于治疗CKD患者的消化系统和肌肉骨骼系统症状。有必要针对CKD患者的特定特征对和剂方疗效开展进一步研究。
